



Setting standards to improve women's health

THE INVESTIGATION AND MANAGEMENT OF THE SMALL-FOR-GESTATIONAL-AGE FETUS

1. Aim

The aim of this guideline is to make recommendations regarding the diagnosis and management of small-for-gestational-age (SGA) fetuses. It does not address multiple pregnancies or pregnancies with fetal abnormalities.

2. Introduction and background

SGA refers to a fetus that has failed to achieve a specific biometric or estimated weight threshold by a specific gestational age. Various thresholds (2.5th, 3rd, 5th, 10th, 15th and 25th centiles and 1.0, 1.5 or 2.0 standard deviations below the population average) are used for various fetal measures. The commonly used threshold is the tenth centile for abdominal circumference and estimated birthweight.¹

SGA fetuses are a heterogeneous group comprising fetuses that have failed to achieve their growth potential (fetal growth restriction, FGR) and fetuses that are constitutionally small. Approximately 50–70% of fetuses with a birthweight below tenth centile for gestational age are constitutionally small,^{2,3} and the lower the centile for defining SGA, the higher the likelihood of FGR. On the other hand, a fetus with growth restriction may not be SGA.⁴

SGA fetuses are at greater risk of stillbirth,^{5–8} birth hypoxia,⁶ neonatal complications⁶ impaired neurodevelopment,^{9,10} and possibly type 2 (non-insulin-dependent) diabetes and hypertension in adult life.^{11–13} The reason that studies on SGA fetuses have shown poor perinatal outcome is likely to be the high incidence of true FGR in this group.^{14,15} However, the vast majority of term SGA infants have no appreciable morbidity or mortality.¹⁶

3. Identification and assessment of evidence

The Cochrane Library, Medline, Embase and the NHS Economic Evaluation Database were searched for diagnostic studies, randomised trials, systematic reviews and meta-analyses and economic studies relating to 'fetal-growth-retardation', 'infant-small-for-gestational-age' and other relevant Medical Subject Heading terms and text-words. The date of the last search was November 2000.

The levels of evidence and the grades of recommendations used in this guideline for effectiveness originate from the US Agency for Healthcare Research and Quality (**Appendix I**). However, this system of grading is not suitable for diagnostic accuracy studies as a randomised controlled trial may not be an appropriate study design for assessing accuracy and therefore a system of grading devised by the NHS Centre for Reviews and Dissemination is used for diagnostic studies (**Appendix II**). Where possible, recommendations are based on, and explicitly linked to the evidence that supports

them. When effectiveness grading (**Appendix I**) is used, the grade is marked with a subscript ‘E’ and when diagnostic accuracy grading (**Appendix II**) is used, the grade is marked with a subscript ‘D’. Areas lacking evidence are highlighted and annotated as ‘Good practice points’.

4. Diagnosis

Methods employed to detect SGA fetuses include abdominal palpation, measurement of symphyseal fundal height, ultrasound biometry, ultrasound estimated fetal weight and ultrasound Doppler flow velocimetry. Four important issues need to be considered with the use of these tests:

- most measurements require an accurate estimation of gestation as a prerequisite
- most tests attempt to diagnose SGA fetuses rather than growth-restricted fetuses¹⁷
- most studies use a one-off measurement (size) to predict SGA while there is evidence that it is the trend (growth) that is of more value in predicting poor fetal outcome¹⁸⁻²⁰
- in most situations no allowance is made for important prognostic factors for SGA, such as maternal height, weight, ethnicity, parity and fetal gender.^{21,22}

It should also be noted that, although an individual test alone may not be predictive of SGA or FGR, a composite of abnormal results such as an ultrasonically small fetus with reduced liquor or abnormal uterine artery Doppler may indicate pathology.

A distinction needs to be made between biometric tests (tests to measure size) and biophysical tests (tests to assess fetal wellbeing). Biometric tests are designed to predict size and, if performed longitudinally, growth, but not wellbeing. Biophysical tests, on the other hand, are not designed to predict size but fetal wellbeing. The presence of fetal wellbeing implies the absence of fetal acidaemia. This distinction implies that the diagnosis of SGA would rely on biometric tests while abnormal biophysical tests are more indicative of FGR than SGA.

4.1 Abdominal palpation

C_D Abdominal palpation has limited diagnostic accuracy to predict an SGA fetus.

Physical examination of the abdomen by inspection and palpation detects as few as 30% SGA fetuses.²³⁻²⁵ Therefore, if SGA is suspected, it is necessary to supplement abdominal palpation with ultrasound biometric tests.

Evidence level III and IV

4.2 Fundal height

B_D Symphyseal fundal height (SFH) measurement has limited diagnostic accuracy to predict an SGA neonate.

Although early studies reported sensitivities of 56–86%²⁶⁻²⁹ and specificities of 80–93%^{26,28-30} for fundal height to predict SGA neonates, a large study³¹ of 2941 women found the sensitivity and specificity to be 27% and 88%, respectively. Serial measurements may improve sensitivity and specificity.³²

Evidence level II and III

The impact on perinatal outcomes of measuring fundal height is uncertain. A systematic review found only one controlled trial with 1639 patients and showed that SFH measurement did not improve any of the perinatal outcomes measured.³³

Evidence level Ib

Low sensitivity, high false positive rates, significant intra- and inter-observer variation^{27,34} make this test alone unsuitable for diagnosis. Therefore, if SGA is suspected, it is necessary to supplement fundal height measurement with ultrasound biometric tests.

✓ Start the measurement by first identifying the variable point, the fundus, and then measuring to the fixed point, the symphysis pubis, with the cm values hidden from the examiner.³⁵

BD Use of a customised fundal height chart improves accuracy to predict an SGA fetus.

A customised SFH chart is adjusted for physiological variables such as maternal height, weight, parity and ethnic group. Use of such charts was found to result in improvement in sensitivity (29% and 48% using non-customised and customised charts, respectively), resulting in increased antenatal detection of SGA babies with a reduction in unnecessary hospital investigations for fetal growth.³⁶ Calculation of customised centiles (both for fundal height and ultrasound growth) requires computer software³⁷ that can be downloaded from the Internet (www.gestation.net), free of charge, for personal or institutional use. These charts can then be printed and incorporated into patient-held records at the time of booking.

Evidence level II

4.3 Ultrasound biometry

BD Use abdominal circumference and estimated fetal weight to diagnose SGA.

Abdominal circumference (AC) and estimated fetal weight (EFW) are the most accurate diagnostic measurements to predict SGA.¹ In high-risk women, AC at less than the tenth centile has sensitivities of 72.9–94.5% and specificities of 50.6–83.8% in the prediction of fetuses with birthweight at less than the tenth centile. The respective figures for EFW are sensitivities of 33.3–89.2% and specificities of 53.7–90.9%.

Several studies have compared various formulas for estimating birthweight.^{38–40} Most of these suffer from methodological and analytical faults.⁴¹ A methodologically sound prospective study by Chien *et al.*,⁴¹ compared four formulas (Shepard *et al.*,⁴² Aoki,⁴³ Campbell and Wilkin⁴⁴ and Hadlock *et al.*⁴⁵) and found the Shepard and Aoki formulas to have the best interclass correlation coefficient, with EFW showing the smallest mean difference from actual birthweight (Table 1). Thus, the Shepard and Aoki formulas are recommended for estimating fetal weight. However, these formulas were validated over birthweights of 2080–4430g and therefore their use outside this range may be inappropriate. The Hadlock formula may be more appropriate when the fetus is expected to be very small.⁴⁶

Evidence level II and III

TABLE 1. FORMULAE FOR ESTIMATION OF FETAL WEIGHT

Shepard's formula:⁴²

$$\text{Log}_{10}\text{EFW} = 1.2508 + (0.166 \times \text{BPD}) + (0.046 \times \text{AC}) - (0.002646 \times \text{AC} \times \text{BPD})$$

Aoki's formula:⁴³

$$\text{EFW} = (1.25647 \times \text{BPD}^3) + (3.50665 \times \text{FAA} \times \text{FL}) + 6.3$$

Hadlock's formula:⁴⁵

$$\text{Log}_{10}\text{EFW} = 1.3596 - 0.00386(\text{AC} \times \text{FL}) + 0.0064(\text{HC}) + 0.00061(\text{BPD} \times \text{AC}) + 0.0425 (\text{AC}) + 0.174 (\text{FL}).$$

EFW = estimated fetal weight (g)

BPD = biparietal diameter (cm)

FAA = fetal abdominal area (cm²)

FL = femur length (cm)

AC = abdominal circumference (cm)

BD Use below tenth centile threshold for both EFW and AC.

A systematic review by Chang *et al.*¹ found that a threshold of the tenth centile had better sensitivities and specificities than other commonly used centiles. Another study where receiver operator curves were used to determine the cut-off to obtain the best sensitivities and specificities found the customised eighth centile for EFW to be the optimal threshold to predict operative delivery for fetal distress and admission to the neonatal care unit.⁴⁷

Evidence level II and III

BD Use customised ultrasound charts.³⁷

Customised birthweight or ultrasound EFW charts that are adjusted for important independent physiological variables, such as maternal weight, maternal height, ethnic group and parity, have better sensitivities for identifying SGA fetuses^{48,49} and identifying morphometric evidence of FGR,⁵⁰ have lower false-positive rates⁵¹ and are predictive of poor perinatal events.^{47,52,53}

Evidence level II and III

BD Use growth velocity in addition to size.

Serial measurements of AC and EFW (growth velocities) are superior to single estimates of AC or EFW in the prediction of FGR (abnormal neonatal ponderal index and skinfold thickness)¹⁸ and predicting poor perinatal outcome.^{19,20} However, use of fetal growth alone to diagnose growth restriction (especially when the interval between the scan is less than two weeks) can lead to high numbers of false positives.⁵³

Evidence level II

The reference charts of fetal biometry based on cross-sectional data are commonly used for assessing growth velocity. However, it is charts based on longitudinal growth studies that reflect growth correctly.⁵⁴ Such charts are available for British population from a well-designed study⁵⁵ and should be used for measuring growth velocity. Use of standard deviation scores, as opposed to simply “eyeballing” the growth pattern, is likely to result in a more reliable and accurate assessment of growth.^{18,19}

Evidence level III

Ratio measures, such as head to abdominal circumference (HC/AC) and femoral length to abdominal circumference (FL/AC) ratios are poorer than AC or EFW alone in predicting SGA1 or neonatal ponderal index.⁵⁶

A systematic review in the Cochrane Database of Systematic Reviews has shown that routine ultrasound after 24 weeks in low-risk pregnancy does not improve perinatal outcome.⁵⁷

Evidence level Ia

4.4 Biophysical tests to diagnose SGA/FGR

All biophysical tests, including amniotic fluid volume (AFV), Doppler, cardiotocography and biophysical scoring, are poor at diagnosing a small or growth-restricted fetus. The diagnostic accuracies of AFV and uterine artery Doppler are given below as examples of limited accuracy of biophysical tests in diagnosing SGA/FGR.

BD AFV has minimal value in diagnosing FGR.

Despite the positive association between AFV and neonatal morphometry, the likelihood ratios remain low.⁵⁸ For amniotic fluid index (AFI), a positive test result has a likelihood ratio (LR) of 2.4 for predicting skinfold thickness below the tenth

Evidence level II

centile and an LR of 1.2 for predicting neonatal ponderal index below 25th centile. The respective negative LRs are 0.6 and 0.8. Serial measurements of AFI have similarly disappointing results (see Table II for interpretation of LRs).

Evidence level II

TABLE 2. INTERPRETATION OF LIKELIHOOD RATIOS

With a positive test result, a LR greater than one increases the probability that SGA or FGR will be present. The greater the LR, the larger the increase in probability of SGA/FGR and the more clinically useful the test result. With a negative test result, a LR of less than one decreases the probability that SGA/FGR is present. The smaller the LR, the larger the decrease and the more clinically useful the test result.

Likelihood ratio	Changes in probability of the condition	Results
> 10 or < 0.1	Large	Conclusive
5–10 or 0.1–0.2	Moderate	Moderately useful
2–5 or 0.2–0.5	Small	Sometimes useful
< 2 or > 0.5	Tiny	Rarely useful
1.0	No change at all	Not useful

AD Uterine artery Doppler has limited use in predicting FGR.

A systematic review with meta-analysis⁵⁹ published in 2000 found that uterine artery Doppler had limited accuracy in predicting FGR and perinatal death. In the low-risk population the pooled LR to predict FGR was 3.6 for a positive test and 0.8 for a negative test. Even in the high-risk population the pooled LRs were 2.7 and 0.7 for positive and negative tests, respectively.

Evidence level I, II and III

Although various Doppler studies of fetal circulation^{18,19} such as aortic to middle cerebral artery pulsatility index ratio are used to predict FGR fetuses, their use needs to be evaluated further in primary and secondary studies.

5. Management

5.1 Assessment for chromosomal defects

When a small fetus is diagnosed, assess for risk of chromosomal defects.

Up to 19% of fetuses with an AC and EFW less than the fifth centile may have chromosomal defects.⁶⁰ The risk is higher when growth restriction is associated with structural abnormalities,⁶⁰ a normal liquor volume or a normal uterine or umbilical artery Doppler.⁶⁰ Therefore, all growth-restricted fetuses need an ultrasound anatomical survey as a minimum. It may also be appropriate to offer karyotyping.

5.2 Surveillance of the small fetus

AE Use umbilical artery Doppler as the primary surveillance tool.

A systematic review with meta-analysis has provided compelling evidence that the use of umbilical artery Doppler to monitor high-risk fetuses reduces perinatal morbidity and mortality.⁶¹ In addition, there was a significant reduction in the number of antenatal admissions and inductions of labour

associated with Doppler use. A study comparing fetal heart-rate monitoring, biophysical profile and umbilical artery Doppler found that only umbilical artery Doppler had value in predicting poor perinatal outcomes in SGA fetuses.⁶² Use of Doppler does not lead to increased interventions as the rates of positive test are low (2.7% of all umbilical artery tests in high-risk women).⁶³ There is evidence that use of Doppler ultrasound to manage SGA fetuses reduces the use of resources compared with cardiotocography.⁶⁴

Screening a low-risk or unselected population by umbilical artery Doppler, however, does not reduce perinatal mortality or morbidity.^{65,66} Thus umbilical artery Doppler is not recommended for screening this population.

A variety of descriptor indices of umbilical arterial Doppler waveform, such as resistance index, systolic/diastolic ratio, pulsatility index and diastolic average ratio, is used for predicting perinatal outcome. An analysis using receiver operator curves in a well-conducted study found resistance index had the best discriminatory ability to predict abnormal outcomes such as SGA, poor Apgar scores, abnormal cardiotocograph, umbilical cord pH and admission to neonatal unit.⁶⁷

Evidence level II

When an anomaly scan and umbilical artery Doppler are normal, the small fetus is likely to be a 'normal small fetus'.^{62,68} Evidence suggests that outpatient management of such fetuses is safe.⁶⁹ In addition, a randomised controlled trial⁷⁰ of two regimens of fetal surveillance for SGA fetuses with normal umbilical artery Doppler found that twice-weekly compared with fortnightly monitoring resulted in earlier deliveries and more inductions of labour with no difference in neonatal morbidity. This suggests frequency of monitoring in SGA fetuses with normal Doppler need not generally be more than once every fortnight. The management of SGA fetuses with abnormal Doppler is discussed in Section 5.3.

Evidence level II

Evidence level Ib

BD Measure liquor volume using either AFI or pocket depth as both tests have similar diagnostic accuracy.

Abnormal liquor volume has been variously defined as single cord-free 1-cm, 2-cm, 1-x-1-cm, 2-x-1-cm and 2-x-2-cm pockets or an AFI below the fifth centile for the gestation or ≤ 5 cm.⁷¹ Both AFI and single-pocket measurements poorly correlate with actual amniotic fluid volume: An AFI of less than 5 cm and single pocket of less than 2 cm have a positive LR of 2.5 each and a negative LR of 0.94 and 0.97, respectively, in the prediction of amniotic volume at less than the fifth centile for gestation.⁷² However, this study used amniocentesis with dye-dilution and spectrophotometry as the gold standard test and there is evidence that this gold standard itself is inaccurate.⁷³

Despite this, a systematic review with meta-analysis⁷⁴ of 18 studies with over 10 000 patients found an antepartum AFI of ≤ 5.0 cm was associated with an increased risk of an Apgar score of less than seven at five minutes (RR = 5.2; 95% CI:2.4–11.3). A poor correlation between AFI and neonatal acidosis was noted in the only study that examined this outcome. Other large studies^{75,76} have shown that a reduction in liquor volume is associated with increased perinatal mortality compared with controls with normal liquor volume.

Evidence level I and III

AE Use biophysical profile and cardiotocography infrequently.

The biophysical profile has not been shown to improve perinatal outcome but sufficient data do not exist to rule out its value: a systematic review⁷⁷ found only four poor-quality studies with fewer than 3000 patients. Authors of the systematic review

Evidence level Ia

concede that to make a meaningful conclusion about the impact of biophysical profile on perinatal mortality, in excess of 10 000 women would need to be studied. However, there is evidence from uncontrolled observational studies that biophysical profile in high-risk women has good negative predictive value, i.e. fetal death is rare in women with a normal biophysical profile.⁷⁸

Evidence level Ia

Given the absence of benefit from randomised trials and that biophysical profile is a time-consuming test, it cannot be recommended for routine monitoring in low-risk/unselected pregnancies or for primary surveillance in SGA fetuses. However, when primary surveillance with umbilical artery Doppler is found to be abnormal, biophysical profile is likely to be useful given its good negative predictive value in high-risk populations.⁷⁸ This recommendation is further supported by evidence that, in high-risk women, the biophysical profile was rarely abnormal when Doppler findings were normal.⁶³

Evidence level Ib

Use of cardiotocography (CTG) antepartum to assess fetal condition is not associated with better perinatal outcome; in fact, a systematic review of randomised trials showed that there was a trend towards increased mortality in the group receiving CTG compared with those who did not.⁷⁹ Computer systems for interpretation of CTG have better accuracy than clinical experts in predicting umbilical acidosis and depressed Apgar scores.^{80,81} However, further evaluation of this technology is required before clinical recommendations could be made regarding its widespread use.⁸²

Evidence level Ia

5.3 Delivery

There is wide variation in practice in the timing of delivery of growth restricted fetuses.⁸³ The Growth Restriction Intervention Trial (GRIT) is attempting to answer this issue and publication is expected in 2003. But thus far there is no evidence from GRIT that early delivery to pre-empt severe hypoxia and acidosis reduces any adverse outcome. The following recommendations may need to be revised when more definitive evidence from GRIT is published.

CE When end diastolic flow is present (PED), delay delivery until at least 37 weeks, provided other surveillance findings are normal.

Absent or reversed end diastolic flow is associated with increased perinatal mortality and morbidity.⁸⁴⁻⁸⁶ The odds ratio for perinatal mortality in pregnancies complicated by absent end diastolic flow (AED) and reversed end diastolic flow (RED) were 4.0 and 10.6, respectively, compared with when end diastolic flow was present.⁸⁴ The incidences of respiratory distress syndrome and necrotising enterocolitis were not increased with absent or reversed end diastolic volume but there was an increase in cerebral haemorrhage, anaemia and hypoglycaemia.⁸⁴

Evidence level IIa

Evidence level IIa

CE When end diastolic flow is absent or reversed, admission, close surveillance and administration of steroids are required. If other surveillance results (biophysical profile, venous Doppler) are abnormal, delivery is indicated. If gestation is over 34 weeks, even if other results are normal, delivery may be considered.

The interval between first occurrence of AED and an abnormal CTG/biophysical profile has ranged from 1–26 days.^{87,88} Gestational age, the presence of hypertension and venous Doppler abnormalities (notably pulsations in the umbilical vein) are the key prognostic factors affecting this interval.⁸⁷ The optimal surveillance strategy in fetuses with AED/RED is unclear. Options include daily CTG/BPP

and/or venous Doppler with delivery when the CTG becomes pathological (decelerations with reduced variability),⁸⁷ the biophysical profile becomes abnormal (≤ 4),⁸⁹ there is reversal of Doppler velocities *in ductus venosus* during atrial contraction⁹⁰ or there are umbilical vein pulsations.⁹¹ Under these circumstances, delivery is likely to be by caesarean section.

CE Use gestation- and birthweight-specific charts to determine the likelihood of survival if early delivery is required.^{92,93}

A study by Draper *et al.*⁹² produced gestation- and birthweight-specific survival rates from 24 weeks of gestation, taking into account factors such as fetal sex, ethnicity and singleton or twin. Use of these tables, rather than ones based on gestation or estimated birthweight alone, is likely to lead to be more accurate estimation of survival. The EPICURE study produced data on developmental disability for extremely preterm infants. Although the data were not specific to growth-restricted infants, they have provided useful information on morbidity when extremely premature delivery is considered.⁹⁴

Evidence level III

AE Administer steroids if gestation is below 36 weeks.

Antenatal steroids significantly reduce the incidence of respiratory distress syndrome.⁹⁵

Evidence level Ia

CE Deliver in a unit where optimal neonatal expertise and facilities are available.⁹⁶

Evidence level IV

A skilled resuscitator who is trained and competent in resuscitation of the newborn should be present at delivery. Where possible, a neonatologist should be present if gestation is extremely preterm or growth restriction is severe.

Evidence level IV

CE Intrapartum monitoring with continuous CTG is recommended.

Although a systematic review⁹⁷ of randomised trials found that intrapartum electronic monitoring did not reduce perinatal mortality, there are substantial observational data to suggest that intrapartum CTG in high-risk populations is likely to be of benefit in reducing perinatal death.⁹⁸

Evidence level Ia and III

Current data are not sufficient to justify a policy of elective caesarean section of all small for gestational age babies.⁹⁹

Evidence level Ia

5.4 Evidence summary for other interventions that have been tried

- Most prenatal interventions do not show any significant effects on perinatal outcome.¹⁰⁰
- Smoking cessation programmes, particularly behavioural strategies, can be effective for a small minority of smokers in increasing birthweight but there are no data to suggest that this intervention improves perinatal outcome.¹⁰¹
- Although a meta-analysis¹⁰² of 13 trials evaluated the use of aspirin in the prevention of growth restriction and found that it reduced the incidence of FGR, only a few studies have used aspirin in the treatment of FGR. These trials are small and have shown conflicting results.^{103,104} Further trials are needed to assess the value of aspirin in the treatment of FGR.
- There is not enough evidence to assess the value of oxygen therapy,¹⁰⁵ nutrient therapy,¹⁰⁶ hospitalisation and bedrest,¹⁰⁷ betamimetics,¹⁰⁸ calcium channel blockers,¹⁰⁹ hormonal therapy¹¹⁰ and plasma volume expansion¹¹¹ in treating growth restriction.

5.5 Plan of management

Local protocols for management of SGA fetus may be developed. An example of a locally developed management plan, in the form of a flow chart, can be viewed on www.ncl.ac.uk/nfmmg/guidelines/sga%20guide.htm.

6. Auditable standards (items iii–vi previously suggested by the RCOG)

- i The outcome for all fetuses classified as severe SGA or FGR should be audited.
- ii All women with evidence of FGR should be offered surveillance with umbilical artery Doppler and biometry as a minimum.
- iii Corticosteroids should be offered to all women who may need delivery between 24 and 36 weeks.¹¹²
- iv All women who smoke should be given full information regarding the significance of smoking in pregnancy and the postnatal period.¹¹²
- v Women, and partners, who wish to stop smoking should be given support – e.g. stop-smoking packages, referral to a self-help group.¹¹²
- vi Neonatal resuscitation: local guidelines should list the equipment to be available for every delivery. Spot checks should be carried out regularly. All items listed should be instantly available. All personnel attending deliveries should receive training in neonatal resuscitation that includes practising practical skills on mannequins and which is repeated yearly.¹¹²

References

1. Chang TC, Robson SC, Boys RJ, Spencer JA. Prediction of the small for gestational age infant: which ultrasonic measurement is best? *Obstet Gynecol* 1992;**80**:1030–8.
2. Ott WJ. The diagnosis of altered fetal growth. *Obstet Gynecol Clin North Am* 1988;**15**:237–63.
3. Wilcox AJ. Intrauterine growth retardation: beyond birthweight criteria. *Early Hum Dev* 1983;**8**:189–93.
4. Chard T, Costeloe K, Leaf A. Evidence of growth retardation in neonates of apparently normal weight. *Eur J Obstet Gynecol Reprod Biol* 1992;**45**:59–62.
5. Cnattingius S, Haglund B, Kramer MS. Differences in late fetal death rates in association with determinants of small for gestational age fetuses: population based cohort study. *BMJ* 1998;**316**:1483–7.
6. McIntire DD, Bloom SL, Casey BM, Leveno KJ. Birthweight in relation to morbidity and mortality among newborn infants. *N Engl J Med* 1999;**340**:1234–8.
7. Kok JH, den Ouden AL, Verloove-Vanhorick SP, Brand R. Outcome of very preterm small for gestational age infants: the first nine years of life. *Br J Obstet Gynaecol* 1998;**105**:162–8.
8. Ounsted M, Moar V, Scott WA. Perinatal morbidity and mortality in small-for-dates babies: the relative importance of some maternal factors. *Early Hum Dev* 1981;**5**:367–75.
9. Taylor DJ, Howie PW. Fetal growth achievement and neurodevelopmental disability. *Br J Obstet Gynaecol* 1989;**96**:789–94.
10. Roth S, Chang TC, Robson S, Spencer JA, Wyatt JS, Stewart AL. The neurodevelopmental outcome of term infants with different intrauterine growth characteristics. *Early Hum Dev* 1999;**55**:39–50.
11. Barker DJ, Gluckman PD, Godfrey KM, Harding JE, Owens JA, Robinson JS. Fetal nutrition and cardiovascular disease in adult life. *Lancet* 1993;**341**:938–41.
12. Barker DJ. The long-term outcome of retarded fetal growth. *Clin Obstet Gynecol* 1997;**40**:853–63.
13. Barker DJ, Osmond C, Simmonds SJ, Wield GA. The relation of small head circumference and thinness at birth to death from cardiovascular disease in adult life. *BMJ* 1993;**306**:422–6.

14. Beattie RB, Johnson P. Practical assessment of neonatal nutrition status beyond birthweight: an imperative for the 1990s. *Br J Obstet Gynaecol* 1994;**101**:842–6.
15. Gardosi J, Mul T, Mongelli M, Fagan D. Analysis of birthweight and gestational age in antepartum stillbirths. *Br J Obstet Gynaecol* 1998;**105**:524–30.
16. Jones RA, Roberton NR. Small for dates babies: are they really a problem? *Arch Dis Child* 1986;**61**:877–80.
17. Altman DG, Hytten FE. Intrauterine growth retardation: let's be clear about it. *Br J Obstet Gynaecol* 1989;**96**:1127–32.
18. Chang TC, Robson SC, Spencer JA, Gallivan S. Identification of fetal growth retardation: comparison of Doppler waveform indices and serial ultrasound measurements of abdominal circumference and fetal weight. *Obstet Gynecol* 1993;**82**:230–6.
19. Chang TC, Robson SC, Spencer JA, Gallivan S. Prediction of perinatal morbidity at term in small fetuses: comparison of fetal growth and Doppler ultrasound. *Br J Obstet Gynaecol* 1994;**101**:422–7.
20. De Jong CL, Francis A, Van Geijn HP, Gardosi J. Fetal growth rate and adverse perinatal events. *Ultrasound Obstet Gynecol* 1999;**13**:86–9.
21. Gardosi J, Mongelli M, Wilcox M, Chang A. An adjustable fetal weight standard. *Ultrasound Obstet Gynecol* 1995;**6**:168–74.
22. De Jong CL, Gardosi J, Baldwin C, Francis A, Dekker GA, Van Geijn HP. Fetal weight gain in a serially scanned high-risk population. *Ultrasound Obstet Gynecol* 1998;**11**:39–43.
23. Tejani N, Mann LI. Diagnosis and management of the small-for-gestational-age fetus. *Clin Obstet Gynecol* 1977;**20**:943–55.
24. Hall MH, Chang PK, MacGillivray I. Is routine antenatal care worth while? *Lancet* 1980;**2**:78–80.
25. Rosenberg K, Grant JM, Hepburn M. Antenatal detection of growth retardation: actual practice in a large maternity hospital. *Br J Obstet Gynaecol* 1982;**89**:12–5.
26. Belizan JM, Villar J, Nardin JC, Malamud J, De Vicurna LS. Diagnosis of intrauterine growth retardation by a simple clinical method: measurement of uterine height. *Am J Obstet Gynecol* 1978;**131**:643–6.
27. Calvert JP, Crean EE, Newcombe RG, Pearson JF. Antenatal screening by measurement of symphysis-fundus height. *BMJ* 1982;**285**:846–9.
28. Cnattingius S, Axelsson O, Lindmark G. Symphysis-fundus measurements and intrauterine growth retardation. *Acta Obstet Gynecol Scand* 1984;**63**:335–40.
29. Mathai M, Jairaj P, Muthurathnam S. Screening for light-for-gestational age infants: a comparison of three simple measurements. *Br J Obstet Gynaecol* 1987;**94**:217–21.
30. Lockwood CJ, Weiner S. Assessment of fetal growth. *Clin Perinatol* 1986;**13**:3–35.
31. Persson B, Stangenberg M, Lunell NO, Brodin U, Holmberg NG, Vaclavinkova V. Prediction of size of infants at birth by measurement of symphysis fundus height. *Br J Obstet Gynaecol* 1986;**93**:206–11.
32. Pearce JM, Campbell S. A comparison of symphysis-fundal height and ultrasound as screening tests for light-for-gestational age infants. *Br J Obstet Gynaecol* 1987;**94**:100–4.
33. Neilson JP. Symphysis-fundal height measurement in pregnancy. *Cochrane Database Syst Rev* 2000;CD000944.
34. Bailey SM, Sarmandal P, Grant JM. A comparison of three methods of assessing inter-observer variation applied to measurement of the symphysis-fundal height. *Br J Obstet Gynaecol* 1989;**96**:1266–71.
35. Gardosi JO, Mongelli JM, Mul T. Intrauterine growth retardation. *Baillieres Clin Obstet Gynaecol* 1995;**9**:445–63.
36. Gardosi J, Francis A. Controlled trial of fundal height measurement plotted on customised antenatal growth charts. *Br J Obstet Gynaecol* 1999;**106**:309–17.
37. GROW: Gestation Related Optimal Weight [PC Windows computer program]. Version 2. Nottingham: PRAM; 1997.

38. Deter RL, Hadlock FP, Harrist RB, Carpenter RJ. Evaluation of three methods for obtaining fetal weight estimates using dynamic image ultrasound. *J Clin Ultrasound* 1981;9:421–5.
39. Deter RL, Harrist RB, Hadlock FP, Carpenter RJ. The use of ultrasound in the assessment of normal fetal growth: a review. *J Clin Ultrasound* 1981;9:481–93.
40. Hill LM, Breckle R, Wolfgram KR, O'Brien PC. Evaluation of three methods for estimating fetal weight. *J Clin Ultrasound* 1986;14:171–8.
41. Chien PF, Owen P, Khan KS. Validity of ultrasound estimation of fetal weight. *Obstet Gynecol* 2000;95:856–60.
42. Shepard MJ, Richards VA, Berkowitz RL, Warsof SL, Hobbins JC. An evaluation of two equations for predicting fetal weight by ultrasound. *Am J Obstet Gynecol* 1982;142:47–54.
43. Aoki M. Fetal weight calculation; Osaka University method. In: Yoshihide C, editor. *Ultrasound in Obstetrics and Gynaecology*. 2nd ed. Kyoto: Kinpodo; 1990.
44. Campbell S, Wilkin D. Ultrasonic measurement of fetal abdomen circumference in the estimation of fetal weight. *Br J Obstet Gynaecol* 1975;82:689–97.
45. Hadlock FP, Harrist RB, Sharman RS, Deter RL, Park SK. Estimation of fetal weight with the use of head, body, and femur measurements - a prospective study. *Am J Obstet Gynecol* 1985;151:333–7.
46. Kaaij MW, Struijk PC, Lotgering FK. Accuracy of sonographic estimates of fetal weight in very small infants. *Ultrasound Obstet Gynecol* 1999;13:99–102.
47. De Jong CL, Francis A, Van Geijn HP, Gardosi J. Customized fetal weight limits for antenatal detection of fetal growth restriction. *Ultrasound Obstet Gynecol* 2000;15:36–40.
48. De Jong CL, Gardosi J, Dekker GA, Colenbrander GJ, Van Geijn HP. Application of a customised birthweight standard in the assessment of perinatal outcome in a high-risk population. *Br J Obstet Gynaecol* 1997;105:531–5.
49. Gardosi J, Chang A, Kalyan B, Sahota D, Symonds EM. Customised antenatal growth charts. *Lancet* 1992;339:283–7.
50. Sanderson DA, Wilcox MA, Johnson IR. The individualised birthweight ratio: a new method of identifying intrauterine growth retardation. *Br J Obstet Gynaecol* 1994;101:310–14.
51. Mongelli M, Gardosi J. Reduction of false-positive diagnosis of fetal growth restriction by application of customized fetal growth standards. *Obstet Gynecol* 1996;88:844–8.
52. Clausson B, Gardosi J, Francis A, Cnattingius S. Perinatal outcome in SGA births defined by customised versus population- based birthweight standards. *BJOG* 2001;108:830–4.
53. Mongelli M, Ek S, Tambyrajia R. Screening for fetal growth restriction: a mathematical model of the effect of time interval and ultrasound error. *Obstet Gynecol* 1998;92:908–12.
54. Mongelli M, Gardosi J. Longitudinal study of fetal growth in subgroups of a low-risk population. *Ultrasound Obstet Gynecol* 1995;6:340–4.
55. Owen P, Donnet ML, Ogston SA, Christie AD, Howie PW, Patel NB. Standards for ultrasound fetal growth velocity. *Br J Obstet Gynaecol* 1996;103:60–9.
56. Colley NV, Tremble JM, Henson GL, Cole TJ. Head circumference/abdominal circumference ratio, ponderal index and fetal malnutrition. Should head circumference/abdominal circumference ratio be abandoned? *Br J Obstet Gynaecol* 1991;98:524–7.
57. Bricker L, Neilson JP. Routine ultrasound in late pregnancy (after 24 weeks' gestation). *Cochrane Database Syst Rev* 2000;CD001451.
58. Owen P, Khan KS, Howie P. Single and serial estimates of amniotic fluid volume and umbilical artery resistance in the prediction of intrauterine growth restriction. *Ultrasound Obstet Gynecol* 1999;13:415–19.
59. Chien PF, Arnott N, Gordon A, Owen P, Khan KS. How useful is uterine artery Doppler flow velocimetry in the prediction of pre-eclampsia, intrauterine growth retardation and perinatal death? An overview. *BJOG* 2000;107:196–208.
60. Snijders RJ, Sherrod C, Gosden CM, Nicolaidis KH. Fetal growth retardation: associated malformations and chromosomal abnormalities. *Am J Obstet Gynecol* 1993;168:547–55.

61. Alfirevic Z, Neilson JP. Doppler ultrasonography in high-risk pregnancies: systematic review with meta-analysis. *Am J Obstet Gynecol* 1995;172:1379–87.
62. Soothill PW, Ajayi RA, Campbell S, Nicolaidis KH. Prediction of morbidity in small and normally grown fetuses by fetal heart rate variability, biophysical profile score and umbilical artery Doppler studies. *Br J Obstet Gynaecol* 1993;100:742–5.
63. Tyrrell SN, Lilford RJ, Macdonald HN, Nelson EJ, Porter J, Gupta JK. Randomized comparison of routine vs highly selective use of Doppler ultrasound and biophysical scoring to investigate high-risk pregnancies. *Br J Obstet Gynaecol* 1990;97:909–16.
64. Haley J, Tuffnell DJ, Johnson N. Randomised controlled trial of cardiotocography versus umbilical artery Doppler in the management of small for gestational age fetuses. *Br J Obstet Gynaecol* 1997;104:431–5.
65. Bricker L, Neilson JP. Routine doppler ultrasound in pregnancy. *Cochrane Database Syst Rev* 2000;CD001450.
66. Goffinet F, Paris-Llado J, Nisand I, Breart G. Umbilical artery Doppler velocimetry in unselected and low-risk pregnancies: a review of randomised controlled trials. *Br J Obstet Gynaecol* 1997;104:425–30.
67. Maulik D, Yarlagadda P, Youngblood JP, Ciston P. Comparative efficacy of umbilical arterial Doppler indices for predicting adverse perinatal outcome. *Am J Obstet Gynecol* 1991;164:1434–9.
68. Bobrow CS, Soothill PW. Fetal growth velocity: a cautionary tale. *Lancet* 1999;353:1460.
69. Nienhuis SJ, Vles JS, Gerver WJ, Hoogland HJ. Doppler ultrasonography in suspected intrauterine growth retardation: a randomized clinical trial. *Ultrasound Obstet Gynecol* 1997;9:6–13.
70. McCowan LM, Harding JE, Roberts AB, Barker SE, Ford C, Stewart AW. A pilot randomized controlled trial of two regimens of fetal surveillance for small-for-gestational-age fetuses with normal results of umbilical artery doppler velocimetry. *Am J Obstet Gynecol* 2000;182:81–6.
71. Magann EF, Chauhan SP, Barrilleaux PS, Whitworth NS, Martin JN. Amniotic fluid index and single deepest pocket: weak indicators of abnormal amniotic volumes. *Obstet Gynecol* 2000;96:737–40.
72. Magann EF, Isler CM, Chauhan SP, Martin JN Jr. Amniotic fluid volume estimation and the biophysical profile: a confusion of criteria. *Obstet Gynecol* 2000;96:640–2.
73. Brans YW, Andrew DS, Dutton EB, Schwartz CA, Carey KD. Dilution kinetics of chemicals used for estimation of water content of body compartments in perinatal medicine. *Pediatr Res* 1989;25:377–82.
74. Chauhan SP, Sanderson M, Hendrix NW, Magann EF, Devoe LD. Perinatal outcome and amniotic fluid index in the antepartum and intrapartum periods: A meta-analysis. *Am J Obstet Gynecol* 1999;181:1473–8.
75. Chamberlain PF, Manning FA, Morrison I, Harman CR, Lange IR. Ultrasound evaluation of amniotic fluid volume. I. The relationship of marginal and decreased amniotic fluid volumes to perinatal outcome. *Am J Obstet Gynecol* 1984;150:245–9.
76. Bastide A, Manning F, Harman C, Lange I, Morrison I. Ultrasound evaluation of amniotic fluid: outcome of pregnancies with severe oligohydramnios. *Am J Obstet Gynecol* 1986;154:895–900.
77. Alfirevic Z, Neilson, JP. Biophysical profile for fetal assessment in high-risk pregnancies. *Cochrane Database Syst Rev* 1997;(4).
78. Dayal AK, Manning FA, Berck DJ, Mussalli GM, Avila C, Harman CR *et al*. Fetal death after normal biophysical profile score: An eighteen-year experience. *Am J Obstet Gynecol* 1999;181:1231–6.
79. Pattison N, McCowan L. Cardiotocography for antepartum fetal assessment. *Cochrane Database Syst Rev* 2000;CD001068.
80. Nielsen PV, Stigsby B, Nickelsen C, Nim J. Computer assessment of the intrapartum cardiotocogram. II. The value of compared with visual assessment. *Acta Obstet Gynecol Scand* 1988;67:461–4.

81. Royal College of Obstetricians and Gynaecologists. *The Use of Electronic Fetal Monitoring*. Evidence-based Clinical Guideline No. 8. London: RCOG; 2001. p. 50, 109–10.
82. Royal College of Obstetricians and Gynaecologists. *The Use of Electronic Fetal Monitoring*. Evidence-based Clinical Guideline No. 8. London: RCOG; 2001. p. 52.
83. When do obstetricians recommend delivery for a high-risk preterm growth-retarded fetus? The GRIT Study Group. Growth Restriction Intervention Trial. *Eur J Obstet Gynecol Reprod Biol* 1996;**67**:121–6.
84. Karsdorp VH, van Vugt JM, Van Geijn HP, Kostense PJ, Arduini D, Montenegro N, *et al*. Clinical significance of absent or reversed end diastolic velocity waveforms in umbilical artery. *Lancet* 1994;**344**:1664–8.
85. Pattinson RC, Norman K, Odendaal HJ. The role of Doppler velocimetry in the management of high-risk pregnancies. *Br J Obstet Gynaecol* 1994;**101**:114–20.
86. Todros T, Ronco G, Fianchino O, Rosso S, Gabrielli S, Valsecchi L, *et al*. Accuracy of the umbilical arteries Doppler flow velocity waveforms in detecting adverse perinatal outcomes in a high-risk population. *Acta Obstet Gynecol Scand* 1996;**75**:113–9.
87. Arduini D, Rizzo G, Romanini C. The development of abnormal heart rate patterns after absent end-diastolic velocity in umbilical artery: analysis of risk factors. *Am J Obstet Gynecol* 1993;**168**:43–50.
88. Forouzan I. Absence of end-diastolic flow velocity in the umbilical artery: a review. *Obstet Gynecol Surv* 1995;**50**:219–27.
89. Divon MY, Girz BA, Lieblich R, Langer O. Clinical management of the fetus with markedly diminished umbilical artery end-diastolic flow. *Am J Obstet Gynecol* 1989;**161**:1523–7.
90. Hecher K, Hackeloer B-J. Cardiotocogram compared to Doppler investigation of the fetal circulation in the premature growth-retarded fetus: longitudinal observations. *Ultrasound Obstet Gynecol* 1997;**9**:152–61.
91. Gudmundsson S, Tulzer G, Huhta JC, Marsal K. Venous Doppler in the fetus with absent end-diastolic flow in the umbilical artery. *Ultrasound Obstet Gynecol* 1996;**7**:262–7.
92. Draper ES, Manktelow B, Field DJ, James D. Prediction of survival for preterm births by weight and gestational age: retrospective population based study [see comments]. *BMJ* 1999;**319**:1093–7.
93. Lemons JA, Bauer CR, Oh W, Korones SB, Papile LA, Stoll BJ, *et al*. Very low birthweight outcomes of the National Institute of Child health and human development neonatal research network, January 1995 through December 1996. NICHD Neonatal Research Network. *Pediatrics* 2001;**107**:E1.
94. Wood NS, Marlow N, Costeloe K, Gibson AT, Wilkinson AR. Neurologic and developmental disability after extremely preterm birth. EPICure Study Group. *N Engl J Med* 2000;**343**:378–84.
95. Royal College of Obstetricians and Gynaecologists. *Antenatal Corticosteroids to Prevent Respiratory Distress Syndrome*. Guideline No. 7. London: RCOG; 1999.
96. Confidential Enquiry into Stillbirths and Deaths in Infancy. Annual Report, 1 January – 31 December 1993. London: HMSO; 1996.
97. Thacker SB, Stroup DF. Continuous electronic heart rate monitoring for fetal assessment during labor. *Cochrane Database Syst Rev* 2000;CD000063.
98. Hornbuckle J, Vail A, Abrams KR, Thornton JG. Bayesian interpretation of trials: the example of intrapartum electronic fetal heart rate monitoring. *BJOG* 2000;**107**:3–10.
99. Grant, A. Elective versus selective caesarean delivery of the small baby. *Cochrane Database Syst Rev* 1997;(2).
100. Gomezoglu M, deOnis M, Villar J. Effectiveness of interventions to prevent or treat impaired fetal growth. *Obstet Gynecol Surv* 1997;**52**:139–45.
101. Dolan-Mullen P, Ramirez G, Groff JY. A meta-analysis of randomized trials of prenatal smoking cessation interventions. *Am J Obstet Gynecol* 1994;**171**:1328–34.
102. Leitich H, Egarter C, Husslein P, Kaidler A, Schemper M. A meta-analysis of low dose aspirin for the prevention of intrauterine growth retardation. *Br J Obstet Gynaecol* 1997;**104**:450–9.

103. Kalinka J, Sieroszewski P, Hanke W, Laudanski T, Suzin J. [Evaluation of the effectiveness of a low-dose aspirin in the treatment of intrauterine growth retardation (IUGR)]. In Polish. *Ginekol Pol* 1999;70:126–34.
104. Newnham JP, Godfrey M, Walters BJ, Phillips J, Evans SF. Low dose aspirin for the treatment of fetal growth restriction: a randomized controlled trial. *Aust N Z J Obstet Gynaecol* 1995;35:370–4.
105. Gulmezoglu AM, Hofmeyr GJ. Maternal oxygen administration for suspected impaired fetal growth. *Cochrane Database Syst Rev* 2000;CD000137.
106. Gulmezoglu AM, Hofmeyr GJ. Nutrient treatment for suspected impaired fetal growth. *Cochrane Database Syst Rev* 1997;(1).
107. Gulmezoglu AM, Hofmeyr GJ. Hospitalisation for bedrest for suspected impaired fetal growth. *Cochrane Database Syst Rev* 1997;(4).
108. Gulmezoglu AM, Hofmeyr GJ. Betamimetics for suspected impaired fetal growth. *Cochrane Database Syst Rev* 2000;CD000036.
109. Gulmezoglu AM, Hofmeyr GJ. Calcium channel blockers for potential impaired fetal growth. *Cochrane Database Syst Rev* 2000;CD000049.
110. Gulmezoglu AM, Hofmeyr GJ. Hormones for suspected impaired fetal growth. *Cochrane Database Syst Rev* 2000;CD000109.
111. Gulmezoglu AM, Hofmeyr GJ. Plasma volume expansion for suspected impaired fetal growth. *Cochrane Database Syst Rev* 2000;CD000167.
112. Benbow A, Semple D, Maresh M. *Effective Procedures in Maternity Care Suitable for Audit*. Manchester: Royal College of Obstetricians and Gynaecologists Clinical Audit Unit; 1997.

Levels of evidence and grades of recommendations used for effectiveness studies

Clinical guidelines are: ‘systematically developed statements which assist clinicians and patients in making decisions about appropriate treatment for specific conditions’. Each guideline is systematically developed using a standardised methodology. Exact details of this process can be found in Clinical Governance Advice No 1: Guidance for the Development of RCOG Green-top Guidelines (available on the RCOG website www.rcog.org.uk/medical/greentopguide.html). These recommendations are not intended to dictate an exclusive course of management or treatment. They must be evaluated with reference to individual patient needs, resources and limitations unique to the institution and variations in local populations. It is hoped that this process of local ownership will help to incorporate these guidelines into routine practice. Attention is drawn to areas of clinical uncertainty where further research may be indicated.

The evidence used in this guideline was graded using the scheme below and the recommendations formulated in a similar fashion with a standardised grading scheme.

Classification of evidence levels for effectiveness studies

Ia	Evidence obtained from meta-analysis of randomised controlled trials.
Ib	Evidence obtained from at least one randomised controlled trial.
IIa	Evidence obtained from at least one well-designed controlled study without randomisation.
IIb	Evidence obtained from at least one other type of well-designed quasi-experimental study.
III	Evidence obtained from well-designed non-experimental descriptive studies, such as comparative studies, correlation studies and case studies.
IV	Evidence obtained from expert committee reports or opinions and/or clinical experience of respected authorities.

Grades of recommendations effectiveness studies

- A_E** Requires at least one randomised controlled trial as part of a body of literature of overall good quality and consistency addressing the specific recommendation. (Evidence levels Ia, Ib)
- B_E** Requires the availability of well-controlled clinical studies but no randomised clinical trials on the topic of recommendations. (Evidence levels IIa, IIb, III)
- C_E** Requires evidence obtained from expert committee reports or opinions and/or clinical experiences of respected authorities. Indicates an absence of directly applicable clinical studies of good quality. (Evidence level IV)

Good practice point

- Recommended best practice based on the clinical experience of the guideline development group.

Classification of evidence levels for diagnostic accuracy studies

- I Evidence obtained from studies with a blind comparison of test to reference standard among an appropriate broadly defined sample of consecutive patients.
- II When any one of the following is present in the study: narrow population spectrum; differential use of reference standard; reference standard not blind; case-control study design.
- III When any two of the following are present in the study: narrow population spectrum; differential use of reference standard; reference standard not blind: case-control study design.
- IV When any three or more of the following are present in the study: narrow population spectrum; differential use of reference standard; reference standard not blind; case-control study design.
- V Expert opinion with no explicit critical appraisal, based on physiology, bench research or first principles.

Grades of recommendations for diagnostic accuracy studies

- A_D** Requires at least one level I study.
- B_D** Requires level II or III studies.
- C_D** Evidence obtained from expert committee reports or opinions and/or clinical experiences of respected authorities. Indicates an absence of directly applicable clinical studies of good quality. (Evidence level IV and V)

Good practice point

- Recommended best practice based on the clinical experience of the guideline development group.

This Guideline was produced on behalf of the Royal College of Obstetricians and Gynaecologists by:

**Dr A Coomarasamy MRCOG, Birmingham; Professor NM Fisk FRCOG, London;
Mr H Gee FRCOG, Birmingham; Professor SC Robson MRCOG, Newcastle-upon-Tyne**
and peer reviewed by:

*RCOG Consumers Forum; Mr JO Gardosi FRCOG, Birmingham; Professor DK James FRCOG, Nottingham;
Professor N Marlow, neonatologist, University Hospital of Nottingham, Nottingham; Dr P Owen MRCOG, Glasgow;
Mr S A Walkinshaw MRCOG, Liverpool; Professor M J Whittle FRCOG, Birmingham.

The final version of this guideline is the responsibility of the Guidelines and Audit Committee of the RCOG.

*The following organisations are represented on the RCOG Consumers Forum:

Association for Improvements in the Maternity Services; Association of Community Health Councils; Family Planning Association; Maternity Alliance; Maternity and Health Links; National Childbirth Trust; National Council for Women; Women's Health.

Valid until November 2005
unless otherwise indicated